Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vascular endothelial growth factor

K H Plate1, P C Warnke

  • 1Department of Neuropathology, Freiburg University Medical School, Germany.

Journal of Neuro-Oncology
|January 24, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CAR-NK cell therapy combined with checkpoint inhibition induces an NKT cell response in glioblastoma.

British journal of cancer·2025
Same author

CD74 regulates complexity of tumor cell HLA class II peptidome in brain metastasis and is a positive prognostic marker for patient survival.

Acta neuropathologica communications·2018
Same author

Diagnostic Accuracy of PET, SPECT, and Arterial Spin-Labeling in Differentiating Tumor Recurrence from Necrosis in Cerebral Metastasis after Stereotactic Radiosurgery.

AJNR. American journal of neuroradiology·2015
Same author

Selective peripheral denervation for cervical dystonia: a historical procedure in the age of deep brain stimulation?

Journal of neurology, neurosurgery, and psychiatry·2015
Same author

Loss of FUBP1 expression in gliomas predicts FUBP1 mutation and is associated with oligodendroglial differentiation, IDH1 mutation and 1p/19q loss of heterozygosity.

Neuropathology and applied neurobiology·2013
Same author

Serum GFAP is a diagnostic marker for glioblastoma multiforme.

Brain : a journal of neurology·2007
Same journal

Intratumoral serotonin and antidepressants in glioblastoma patients: narrowing the uncertainties.

Journal of neuro-oncology·2026
Same journal

Fractionated stereotactic radiotherapy (fSRT) for symptomatic WHO grade 1 cavernous sinus meningiomas: long-term local control, clinical response, and toxicity outcomes.

Journal of neuro-oncology·2026
Same journal

A label-free nanoplasmonic biosensor for intraoperative discrimination of tumor margins in brain metastases surgery.

Journal of neuro-oncology·2026
Same journal

Endovascular treatment of tumor-related dural sinus stenosis, venous outflow obstruction, and secondary intracranial hypertension: a systematic review of the literature.

Journal of neuro-oncology·2026
Same journal

Survival outcomes and a prognostic nomogram in EGFR-mutant non-small cell lung cancer with leptomeningeal metastasis: a real-world cohort study.

Journal of neuro-oncology·2026
Same journal

Correction to: cGAS-STING agonists in preclinical glioblastoma animal models: a systematic review of tumor microenvironment modulation and survival outcomes.

Journal of neuro-oncology·2026
See all related articles

Hypoxia drives vascular endothelial growth factor (VEGF) in glioblastomas, promoting tumor growth and swelling. Inhibiting the VEGF pathway may treat these aggressive brain tumors.

Area of Science:

  • Neuro-oncology
  • Molecular biology
  • Cancer research

Background:

  • Vascular endothelial growth factor (VEGF) is a key factor in angiogenesis and vascular permeability.
  • VEGF is highly expressed in human glioblastomas, particularly in cells near necrotic areas.
  • Hypoxia significantly upregulates VEGF gene expression in vitro and is implicated in vivo.

Purpose of the Study:

  • To investigate the role of hypoxia in driving VEGF expression in glioblastomas.
  • To explore therapeutic strategies targeting the VEGF pathway in glioblastoma.

Main Methods:

  • Analyzing VEGF expression in glioblastoma cells under hypoxic conditions.
  • Investigating the in vivo correlation between hypoxia, VEGF, and tumor characteristics.
  • Developing approaches to disrupt the VEGF/VEGF receptor signaling pathway.

Related Experiment Videos

Main Results:

  • Hypoxia enhances VEGF gene expression approximately tenfold in vitro.
  • Hypoxia is suggested to be the primary driver of VEGF expression in glioblastoma cells in vivo.
  • VEGF is identified as a critical factor for tumor angiogenesis and edema in glioblastomas.

Conclusions:

  • Hypoxia is a crucial regulator of VEGF in glioblastomas.
  • Targeting the VEGF signaling pathway is a promising therapeutic strategy for glioblastoma.
  • Inhibiting VEGF may reduce tumor angiogenesis and edema in glioblastoma patients.